Shanghai MicroPort MedBot (2252.HK) Q4 2025 Earnings Report

Shanghai MicroPort MedBot Group delivered a standout Q4 2025 top-line performance, with revenue of 369.12 million CNY, up 367.2% year over year and 110.1% quarter over quarter, signaling substantial early demand traction for its robotics platforms in the Chinese and European markets. The company achieved a gross margin of 37.1% (136.81 million CNY gross profit on 369.12 million CNY revenue), reflecting favorable product mix and scale effects as the installed base for Toumai, DFVision, Honghu, ROne, iSRobot, and related systems expands. However, profitability remains pressured by a high cadence of research and development and related operating expenses; Q4 2025 EBITDA was negative 26.59 million CNY (-7.2% of revenue), operating income was -81.65 million CNY (-22.12% margin), and net income declined to -134.03 million CNY (-36.31% margin) with an EPS of -0.13. The year culminates with a robust liquidity position and a debt umbrella that leaves the firm net cash positive, providing a buffer as the company continues to invest in pipeline products and commercialization capabilities.

The quarterly cadence across 2025 shows a sharp re-acceleration in revenue (Q1 2025 to Q4 2025), a substantial R&D commitment (Q4 R&D spend of 125.24 million CNY; full-year R&D spend approximately 330.5 million CNY), and a gradual improvement in gross margin from 24.8% in 2024 to the 37.1% level in Q4 2025. Management commentary suggests a strategy centered on expanding adoption of its surgical robotics platforms, scaling international commercialization, and accelerating product development for high-value indications (e.g., TAVR robotics, transbronchial robots). The balance sheet remains resilient, with 640.42 million CNY in cash and cash equivalents, total debt of 426.37 million CNY, and a net cash position of approximately -214.05 million CNY, implying meaningful liquidity headroom to support ongoing R&D and go-to-market investments.